# US 2021/0071253 A1 · Heritable epigenetic modifications as markers of chemotherapy exposure

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0071253 A1
- Document ID: US20210071253A1
- Status: Published application
- Kind: A1
- Application number: 16/939,287
- Filed: 2020-07-27
- Published: 2021-03-11
- Earliest claimed: 2016-03-01
- Assignees: Washington State University; Seattle Children's Hospital (dba Seattle Children's Research Institute)
- Applicants: Washington State University; Seattle Children's Hospital DBA Seattle Children's Research Institute
- Inventors: Michael K. Skinner; Margarett Shnorhavorian
- Web page: https://patentgrep.com/patent/US20210071253A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/154: Methylation markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Provided herein are epigenetic modifications that are associated with prior exposure to chemotherapy agents. In particular, differential DNA methylation regions (DMRs) that are characteristic of, and can thus be used to identify and/or treat, a male subject who has undergone chemotherapy are provided. The DMRs are used to screen for pregnancy complications, infertility, and passage of heritable mutations to an infant.

## Claims

### Claim 1

A method, comprising:
obtaining a sperm sample from a subject;
isolating a nucleic acid from at least a portion of said sperm sample;
detecting a methylation alteration present in at least a portion of said nucleic acid comprising a differential DNA methylation region (DMR), wherein said DMR is listed in Table 10; and
comparing said methylation alteration using a computer comprising one or more processors, one or more memories, and instructions disposed thereupon to a reference methylation alteration in a corresponding DMR listed in Table 10.

### Claim 2 (depends on 1)

The method of claim 1, further comprising administering a treatment to said subject.

### Claim 3 (depends on 2)

The method of claim 2, wherein said subject has or is suspected of having a chemical exposure.

### Claim 4 (depends on 2)

The method of claim 2, further comprising determining a likelihood of having a chemical exposure in said subject at least based in part on said detecting.

### Claim 5 (depends on 2)

The method of claim 2, wherein said subject has or is suspected of having a risk of infertility.

### Claim 6 (depends on 5)

The method of claim 5, further comprising determining said risk of infertility in said subject at least based in part on said detecting.

### Claim 7 (depends on 2)

The method of claim 2, wherein said subject has or is suspected of having a risk of passing a heritable mutation to an offspring of said subject.

### Claim 8 (depends on 7)

The method of claim 7, further comprising determining said risk of passing said heritable mutation at least based in part on said detecting.

### Claim 9 (depends on 7)

The method of claim 7, wherein said heritable mutation leads to pregnancy complications or mutations in an infant of said subject.

### Claim 10 (depends on 1)

The method of claim 1, wherein said detecting comprises detecting a methylation alteration of said at least a portion of said nucleic acid sequence comprising a DMR, wherein said DMR is listed in Table 6.

### Claim 11 (depends on 1)

The method of claim 1, wherein said detecting comprises detecting a methylation alteration of said at least a portion of said nucleic acid comprised in two or more, three or more, four or more, five or more, six or more, ten or more, fifteen or more, twenty or more, thirty or more, forty or more, fifty or more, sixty or more, seventy or more, eighty or more, ninety or more, one hundred or more, two hundred or more, three hundred or more, four hundred or more, five hundred or more, six hundred or more, seven hundred or more, eight hundred or more, nine hundred or more, one thousand or more, or two thousand or more DMRs listed in Table 10.

### Claim 12 (depends on 10)

The method of claim 10, wherein said detecting comprises detecting a methylation alteration of said at least a portion of said nucleic acid sequence comprised in two or more, three or more, four or more, five or more, six or more, ten or more, fifteen or more, twenty or more, thirty or more, forty or more, fifty or more, sixty or more, seventy or more, eighty or more, ninety or more, or one hundred or more DMRs listed in Table 6.

### Claim 13 (depends on 10)

The method of claim 10, wherein said detecting comprises detecting 1-135 DMRs listed in Table 6.

### Claim 14 (depends on 10)

The method of claim 10, wherein said detecting comprises detecting 1-75 DMRs listed in Table 6.

### Claim 15 (depends on 10)

The method of claim 10, wherein said detecting comprises detecting 50-135 DMRs listed in Table 6.

### Claim 16 (depends on 3)

The method of claim 3, wherein said chemical exposure comprises chemotherapy.

### Claim 17 (depends on 16)

The method of claim 16, wherein said chemotherapy comprises cisplatin, ifosfamide, or both.

### Claim 18 (depends on 16)

The method of claim 16, wherein said chemotherapy occurred at least 10 years ago.

### Claim 19 (depends on 1)

The method of claim 1, wherein said detecting comprises performing methylated DNA immunoprecipitation (MeDIP).

### Claim 20 (depends on 19)

The method of claim 19, wherein said MeDIP comprises employing an antibody that binds to a methylated base.

### Claim 21 (depends on 20)

The method of claim 20, wherein said methylated base is 5-methylated base.

### Claim 22 (depends on 21)

The method of claim 21, wherein said 5-methylated base is a 5-methylated cytosine (5-mC).

### Claim 23 (depends on 1)

The method of claim 1, where said detecting comprises next generation sequencing (NGS).

### Claim 24 (depends on 1)

The method of claim 1, wherein said DMR is associated with a gene listed in Table 8.

### Claim 25 (depends on 1)

The method of claim 1, wherein said DMR is associated with a gene listed in Table 9.

### Claim 26 (depends on 1)

The method of claim 1, wherein said nucleic acid comprises a fragment size of about 200 bp to about 800 bp.

### Claim 27 (depends on 2)

The method of claim 2, wherein said treatment is for chemical exposure.

### Claim 28 (depends on 1)

The method of claim 1, wherein said methylation alteration comprises an increased methylation level.

### Claim 29 (depends on 1)

The method of claim 1, wherein said methylation alteration comprises a decreased methylation level.

### Claim 30 (depends on 1)

The method of claim 1, wherein said reference methylation alteration in a corresponding DMR is obtained from at least a portion of a nucleic acid from at least a portion of a sperm sample from a healthy subject.

### Claim 31 (depends on 1)

The method of claim 1, wherein said DMR comprises a CpG locus.

### Claim 32 (depends on 31)

The method of claim 31, wherein said the CpG locus is located in a promoter region of a gene.

### Claim 33 (depends on 31)

The method of claim 31, wherein said the CpG locus is located in an exon region of a gene.

### Claim 34 (depends on 31)

The method of claim 31, wherein said the CpG locus is located in an intro region of a gene.

### Claim 35 (depends on 31)

The method of claim 31, wherein said the CpG locus is located near a gene.
